- In December 2024, ZEISS announced a partnership with Mindpeak, a leader in AI-driven pathology solutions, to co-develop an integrated Multiplex Immunofluorescence (mIF) platform tailored for pathologists working in research, diagnostics, and clinical settings. Leveraging Mindpeak’s expertise in AI-based tissue image analysis—particularly its clinically validated algorithms—alongside ZEISS’s advanced imaging instruments and software, the collaboration aims to unify both companies’ technologies into a comprehensive solution. This joint effort is designed to deliver greater value to users while addressing the needs of diverse market segments
- In January 2023, Agilent Technologies announced a strategic partnership with Akoya Biosciences to develop multiplex immunohistochemistry (mIHC) diagnostic solutions and commercialize end-to-end workflow systems for tissue biomarker analysis in clinical research. The collaboration integrates Agilent’s Dako Omnis autostaining instrument with Akoya’s PhenoImager HT imaging platform, creating a comprehensive solution for multiplex chromogenic and immunofluorescent assays. This partnership aims to support companion diagnostics and enable biopharma companies to accelerate biomarker discovery and patient stratification in precision cancer therapeutics
- In September 2022, Ultivue and ngTMA entered a collaborative agreement to provide advanced multiplex and spatial analysis services for clinical research applications. This partnership combines Ultivue’s expertise in multiplex biomarker assays with ngTMA’s capabilities in tissue microarray (TMA) construction, aiming to deliver high-throughput, spatially-resolved tissue analysis for translational and clinical research, especially in oncology and immuno-oncology studies
- In November 2022, Evident Scientific (formerly part of Olympus) and Ultivue announced a strategic collaboration to integrate Ultivue’s multiplexing technology with Evident’s advanced imaging platforms. The partnership is focused on streamlining spatial phenotyping workflows by enabling high-content image acquisition and analysis, offering pathologists and researchers a more effective solution for biomarker localization and spatial tissue profiling
- In October 2022, Fluidigm Corporation (now Standard BioTools) announced a co-marketing agreement with Ultivue to combine their respective technologies for enhanced multiplex biomarker detection and spatial tissue analysis. This collaboration aims to deliver integrated solutions that pair Ultivue’s proprietary assay development with Fluidigm’s Imaging Mass Cytometry (IMC) platform, supporting drug discovery and translational research through high-resolution, quantitative tissue imaging
